0
0
Read Time:30 Second
Doha – July 17, 2024: Students at Weill Cornell Medicine-Qatar (WCM-Q) have made a significant contribution to the field by publishing a study that delves into the effects of Ozempic-type drugs on the interconnected health challenges of obesity, diabetes, and cancer.
Ozempic, the brand name of a drug called semaglutide, belongs to a class of medications called glucagon-like peptide-1 receptor (GLP-1R) agonists. These medications have recently become extremely well-known as treatments for managing obesity and diabetes by helping to control feelings of hunger, reduce food consumption, and promote weight loss.
Beyond the effects on hunger,
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %